RCMW Group Inc Ordinary Shares Stock (OTC: RCMW)

RCMW Group Inc Ordinary Shares Stock (OTC:RCMW), Trade Ideas

RCMW Group Inc Ordinary Shares

Rosenblatt analyst Barton Crockett maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and lowers the price target from $554 to $540.

News

Price Target

Analyst Ratings

NFLX

Rosenblatt Maintains Neutral on Netflix, Lowers Price Target to $540

Nike Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is reportedly&nbsp;on the brink of&nbsp;finalizing a substantial endorsement deal with basketball sensation Caitlin Clark ahead of her anticipated professional debut scheduled for May.
Clark, recently selected as the first overall pick in the WNBA draft by the Indiana Fever following a remarkable collegiate career, had previously enjoyed sponsorship from Nike under a name, image, and likeness arrangement while attending the University of Iowa, reported&nbsp;<a target="_blank" href="https://www.bloomberg.com/news/articles/2024-04-18/nike-nke-caitlin-clark-endorsement-deal-getting-closer?srnd=industries-v2&amp;sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a>.
Set to join the ranks of the world&#8217;s largest sportswear company, Clark is poised to launch her&nbsp;own&nbsp;signature line of footwear, aligning with Nike&#8217;s strategy of cultivating a roster of young basketball talents.
This move comes as renowned athletes such as LeBron James and Kevin Durant approach the twilight of their careers.
Nike&#8217;s CEO, John Donahoe, highlighted Clark&#8217;s potential during a recent conference call with investors and analysts.
The brand showcased Clark in a commercial aired in&nbsp;March,&nbsp;following her record-breaking performance in NCAA basketball.
As per the report, major athletic brands are&nbsp;turning their focus to&nbsp;women&#8217;s sports, drawn by surging viewership and the emergence of new stars. Despite this, female athletes&nbsp;being granted&nbsp;sneaker lines&nbsp;remains&nbsp;relatively rare.
In September, Nike debuted a signature shoe with New York Liberty standout Sabrina Ionescu, a move praised by Donahoe for its broad appeal across genders.
Meanwhile,&nbsp;Puma SE&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/PMMAF#OTC">PMMAF</a>) has a similar arrangement with Ionescu&#8217;s teammate, two-time MVP Breanna Stewart, the report added.
Price Action: NKE shares closed higher by 0.95% at $95.74 on Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by pixfly on Shutterstock

Media

General

PMMAF

Nike's Sneaker Coup: Reportedly Nears Lucrative Deal With Basketball Sensation Caitlin Clark

VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) announces the signing of a cooperation agreement with Mobivia, one of Europe&#39;s leading automotive repair and maintenance brands, expanding access to a comprehensive aftersales service network for VinFast customers in France and Germany.

Tech

Vinfast Expands Access To Comprehensive Aftersales Network In France And Germany Through Agreement With Mobivia

Baird analyst David Koning maintains TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) with a Neutral and lowers the price target from $10 to $9.

TIXT

Baird Maintains Neutral on TELUS Intl, Lowers Price Target to $9

Company announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410&nbsp;(AAV-hRORA)&mdash;a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). GA affects approximately 1 million people in the United States alone.
&quot;We are very enthusiastic about the potential of OCU410 as a one-time, gene-agnostic option for the treatment of GA,&quot; said Dr. Huma Qamar, Chief Medical Officer of Ocugen. &quot;OCU410 regulates multiple pathways involved with the disease, including lipid metabolism, inflammation, oxidative stress, and membrane attack complex (complement) with a single sub-retinal injection.&quot;

OCGN

Ocugen Says It Has Completed Dosing of Subjects With Geographic Atrophy In Cohort 2 Of Phase 1/2 ArMaDa Clinical Trial Of OCU410—A Modifier Gene Therapy

Baird analyst David Koning maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) with a Outperform and raises the price target from $95 to $98.

Baird Maintains Outperform on Block, Raises Price Target to $98

Baird analyst David Koning maintains IBEX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBEX#NASDAQ">IBEX</a>) with a Outperform and lowers the price target from $21 to $20.

IBEX

Baird Maintains Outperform on IBEX, Lowers Price Target to $20

Biotech

Earnings

Health Care

YS Biopharma Co 9M 2024 EPS Loss Of RMB (1.04) Versus RMB (2.71) YoY

Citigroup analyst Keith Horowitz maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Buy and raises the price target from $39 to $43.

Citigroup Maintains Buy on Citizens Financial Group, Raises Price Target to $43

Peter Schiff, renowned economist and crypto skeptic, recently expressed his views on Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38315201/bitcoin-ethereum-edge-lower-following-jobless-claims-data-nervos-network-becomes-top-loser">recent volatility</a> and its implications on the cryptocurrency&#8217;s status as a safe haven asset.
What Happened: Schiff took to X, formerly Twitter, on Friday to highlight the significant difference in the reactions of Bitcoin and gold to escalating geopolitical tensions in the Middle East and other macro events. He pointed out that while the Dow Jones Industrial Average fell 1.5%, Bitcoin tanked 6%, whereas gold rose 1.5%. 
&#8220;Bitcoin is not the safe haven asset it&#8217;s promoted to be,&#8221; he wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">What&#39;s significant is not that <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> rallied back with other risk assets, but that when the Dow initially fell 1.5% in a knee-jerk reaction to escalating geopolitical risk, Bitcoin tanked 6%. In contrast <a href="https://twitter.com/hashtag/gold?src=hash&amp;ref_src=twsrc%5Etfw">#gold</a> rose 1.5%. Bitcoin is not the safe haven asset it&#39;s promoted to be.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1781245311320539641?ref_src=twsrc%5Etfw">April 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38269843/dogecoin-shiba-inu-dogwifhat-among-top-picks-for-this-researchers-meme-coin-supercycle-the?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin, Shiba Inu, Dogwifhat Among Top Picks For This Researcher&#8217;s &#8216;Meme Coin Supercycle&#8217; Thesis</a>
On Thursday, Bitcoin moved lower, with <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38315201/bitcoin-ethereum-edge-lower-following-jobless-claims-data-nervos-network-becomes-top-loser">cryptocurrency prices falling below</a> the key $63,000 level after U.S. initial jobless claims remained unchanged from the previous week at 212,000 for the week ending April 18, which was below market expectations of 215,000.
Why It Matters: Earlier this week, he <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38265256/peter-schiff-challenges-bitcoins-100k-prediction-as-crypto-linked-stocks-languish-i">questioned the predictions of Bitcoin </a>reaching $100K, pointing out that Bitcoin-related equities are in bear markets.
Schiff&#8217;s comments come in the wake of a recent downturn in Bitcoin&#8217;s price, which fell below the $63,500 mark. His observations underscore the volatility of Bitcoin, contrasting it with the stability of gold in times of geopolitical unrest.
Despite the recent slump, some analysts, like Michaël van de Poppe, <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38327607/bitcoin-analyst-predicts-significant-chance-of-price-bounce-amid-fading-hype-narratives-wi">predict a significant rebound</a> in Bitcoin&#8217;s price. Van de Poppe wrote, "Pretty significant chance #Bitcoin will be bouncing from this area upwards for some relief. The hype is slowly fading away for Bitcoin as the halving is approaching and narratives will change."
Price Action: According to data <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">from Benzinga Pro</a>, Bitcoin is presently trading at $64,515, representing an increase of 4.5% over the last 24 hours. It has surged 120% in the past one year. 
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38299089/trump-related-maga-memecoin-onboards-roger-stone-as-partner?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump-Related MAGA Memecoin Onboards Roger Stone As Partner</a>
Image via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Peter Schiff Slams Bitcoin For Not Being The 'Safe Haven Asset It's Promoted To Be' After BTC Tanked 6% Following Jobless Claims Data

YS Biopharma Co 9M 2024 Sales Of $61.9M

Baird analyst Jeffrey Meuler maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Outperform and lowers the price target from $275 to $260.

Baird Maintains Outperform on Equifax, Lowers Price Target to $260

JMP Securities analyst Jordan Bender maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Market Outperform and lowers the price target from $65 to $62.

JMP Securities Maintains Market Outperform on Caesars Entertainment, Lowers Price Target to $62

Baird analyst Colin Sebastian maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Neutral and raises the price target from $60 to $65.

CVNA

Baird Maintains Neutral on Carvana, Raises Price Target to $65

The companies include&nbsp;Centre Technologies Holdings, LLC, Pearl Meyer&nbsp;Topco, LLC, SI East, LLC,&nbsp;Slick Innovations, LLC and Bolder Panther Group, LLC.

MAIN

Main Street Capital Corporation Says It Invested $36.6M In Five Existing Lower Middle Market Portfolio Companies

Baird analyst Luke Junk maintains Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) with a Neutral and lowers the price target from $295 to $282.

Baird Maintains Neutral on Snap-on, Lowers Price Target to $282

Sundar Pichai,&nbsp;Google's&nbsp;CEO, has announced a significant restructuring of the company's leadership and operational divisions to accelerate its&nbsp;<a target="_blank" href="https://www.benzinga.com/news/23/12/36135857/why-is-google-parent-alphabet-stock-soaring-today" rel="noreferrer noopener">artificial intelligence (AI) development</a>.&nbsp;
This move is in response to criticisms that the company is lagging behind competitors like&nbsp;Microsoft Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).&nbsp;
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19034024/newplot-19.png" alt="" class="wp-image-299375" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19034024/newplot-19.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19034024/newplot-19-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
The reorganization will see all AI-related teams, including the development of the Gemini chatbot, consolidated under the DeepMind division led by Demis Hassabis.
This consolidation encompasses research, model development, computing resources, and regulatory compliance teams, the Financial Times&nbsp;<a target="_blank" href="https://www.ft.com/content/26d39c4a-a6c7-4703-8184-271fde7f717e" rel="noreferrer noopener">reported</a>.
In a communication to employees, later shared in a blog post, Pichai detailed the consolidation of models, research, and responsible AI teams under Google DeepMind, the company's premier AI division.&nbsp;
The move aims to unify efforts on Google's AI models, Gemini and Gemma, by combining resources from Google Research and DeepMind into a single team.
Additionally, Pichai introduced a new unified Platform and Devices team, merging hardware, software, and AI initiatives, including projects like Android, Chrome, search, and photos headed by Rick Osterloh.&nbsp;
Bloomberg reports that the restructuring also includes the formation of a central Trust and Safety team dedicated to the rigorous testing and evaluation of AI systems.
This shakeup aims to streamline Google's structure, enhance its product innovation pace, and facilitate quicker decision-making processes.&nbsp;
Hiroshi Lockheimer will transition from overseeing Android to focusing on new projects, with Sameer Samat replacing him.
This overhaul marks the most significant changes at&nbsp;Alphabet Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Google's parent company, since integrating its DeepMind and Google Brain AI units the previous year. It signifies a considerable expansion of Hassabis's influence over Google's AI endeavors.
Google seeks to overcome recent challenges, notably the controversy surrounding&nbsp;<a target="_blank" href="https://www.benzinga.com/news/23/12/36154624/whats-going-on-with-google-parent-alphabet-stock-friday" rel="noreferrer noopener">Gemini's image generation</a>.&nbsp;
It&nbsp;led to criticisms of its AI capabilities compared to rivals like OpenAI,&nbsp;Meta Platforms Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Anthropic.&nbsp;
<a target="_blank" href="https://www.benzinga.com/news/24/04/38278168/googles-growth-ignited-by-ai-and-premium-video-ads-analyst-predicts-brighter-future" rel="noreferrer noopener">Analysts have flagged</a>&nbsp;Alphabet's strategic investments in cloud, hardware, and AI as&nbsp;key&nbsp;drivers for its multi-year growth. These investments counter the narratives around competitive threats, underscoring Google's strong foundation in its core businesses.&nbsp;
Alphabet's focus on AI and the continued evolution of CTV will foster a positive reassessment of its shares.
<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37830193/google-and-apples-potential-ai-partnership-sparks-analyst-optimism-could-reinforce-" rel="noreferrer noopener">Analysts also highlighted</a>&nbsp;the potential collaboration between&nbsp;Apple Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Google&nbsp;could&nbsp;significantly enhance iOS features by incorporating advanced Gen-AI capabilities, including a more sophisticated version of Siri and new AI services like chatbots and image generators.
GOOGL stock gained 50% in the last 12 months. Investors can gain exposure to the stock via&nbsp;Vanguard Communication Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>) and&nbsp;IShares Global Comm Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXP#NYSE">IXP</a>).
Price Action:&nbsp;GOOGL shares closed higher by 0.35% at $156.01 on Thursday.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38322252/amazon-analyst-predicts-lead-in-ai-revolution-with-strategic-cost-efficiency-and-tech-innovations" rel="noreferrer noopener">Amazon Analyst Predicts Lead in AI Revolution with Strategic Cost Efficiency and Tech Innovations</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Management

AAPL

GOOG

GOOGL

iShares Trust S&P Global Telecommunications Sector Index Fund

MSFT

Google's DeepMind to Lead Unified AI Charge as Company Seeks to Outpace Microsoft

Merck Says Health Canada Approved KEYTRUDA Combination As First-line Treatment For Adult Patients With Locally Advanced Unresectable Or Metastatic HER2-Negative Gastric Or GEJ Adenocarcinoma

Baird analyst Robert Mason maintains Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) with a Neutral and raises the price target from $151 to $180.

Baird Maintains Neutral on Badger Meter, Raises Price Target to $180

The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.
The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR&#39;s granted patent&nbsp;<a href="https://www.globenewswire.com/Tracker?data=2Ct1VlHTN7s9kKLzuYjjceoprNCVAnRgUXOy9TbpbOkved0Wb0LKvKfwvcte2z9f0uiOJYBnah3BwVLHtWsFlh14ptX8M2hNCCt0TV84gUnQybAQSnfAzumrPTbCoa85TdnYF5Bje4KPY3O1eTz0OA==" target="_blank">EP 3 507 366 B1</a>,&nbsp;which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR&#39;s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The Opposition Division of the EPO held a public hearing on April 17, 2024, and ruled such that ProQR&#39;s strong IP position on chemically modified editing oligonucleotides was maintained.
The patent contains broad platform claims including: &quot;An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell&hellip;&quot;, which protects ProQR&#39;s proprietary ADAR mediated RNA editing platform Axiomer.
&quot;This decision further supports the confidence we have in the broad scope conferred by our IP estate protecting our proprietary Axiomer ADAR-mediated RNA editing technology platform, and the use of chemically modified oligonucleotides to increase stability and recruit endogenous ADAR to edit the target adenosine,&quot; said Ren&eacute; Beukema, Chief Corporate Development Officer and General Counsel. &quot;Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we progress our science, platform, and pipeline.&quot;
ProQR invented the use of endogenous ADAR in RNA editing in 2014 and filed a first patent application in that same year.&nbsp;